Sumary of Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models:
- The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus, has become a global health emergency.
- On the 14th post-priming injection day, total specific IgG levels were determined using ELISA.
- Related StoriesNorthern pig-tailed macaques were used to test the Nanocovax vaccine’s immunogenicity.
- Monkeys were given Nanocovax at various dosages twice through Intramuscular injection or PBS as a negative control.
- Blood samples were taken on days 14, 28, and 45 after the booster injection on day 7 to assess antibody levels.
- The levels of S protein-specific IgG in the 25-, 50-, 75-, and 100-g groups were marginally higher on day 28 after priming injection than in the control group, at 39.02-fold, 68.58-fold, 87.82-fold, and 97.37-fold, respectively, than in the control group.